Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TOP2A | P11388 | 2/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476725 | 0.89 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL4035056 | 0.88 | NISCH (0.68) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL9828172 | 0.86 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8195024 | 0.81 | NISCH (0.67) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1724885 | 0.80 | NISCH (0.71) | NISCHLMNARECQLTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL11755591 | 0.79 | TOP2A (0.73) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8141372 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL17826831 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL771337 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1209074 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | claimed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | disclosed |
| US-11092549-B2 | Fluorescent probes for drug permeability in gram negative bacteria | SAINT LOUIS UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-11092549-B2 | Fluorescent probes for drug permeability in gram negative bacteria | SAINT LOUIS UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-20180170861-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-21 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| WO-2010065090-A2 | ANTIMICROBIALS | KING TECHNOLOGY, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100140185-A1 | Wastewater treatment | HILL JOHN | 2010-06-10 | — | — | US | disclosed |
| US-20100143427-A1 | Antimicrobial Surfaces | KING JOSEPH A | 2010-06-10 | — | — | US | disclosed |
| US-20100143495-A1 | Antimicrobial body affecting products | KING TECHNOLOGY, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, LTB4R | NISCH 371/4885LMNA 1846/4885RECQL 3952/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NISCH 4556/4885LMNA 3015/4885RECQL 2017/4885 |
| US-20180170861-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF | PTPA, EPM2A, PTPRA | NISCH 4308/4885LMNA 2339/4885RECQL 1570/4885 |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | NISCH 153/4885LMNA 1824/4885RECQL 3114/4885 |
| US-11092549-B2 | Fluorescent probes for drug permeability in gram negative bacteria | SLC47A2, SLC47A1, ABCB11 | NISCH 455/4885LMNA 2325/4885RECQL 1768/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | NISCH 4572/4885LMNA 3115/4885RECQL 2141/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | NISCH 4572/4885LMNA 3115/4885RECQL 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.